NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/05/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization202.38 mln
Float116 mln
Earnings Date09/01/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
8.00
Transformational upside
Relative Strength
19
/ 100
Significantly lagging
Debt / Equity
0.01
Debt-free
ROE
-21.30
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
NovaBridge Biosciences is a U.S.-based biotechnology company founded in 2014 and headquartered in Rockville, Maryland, that develops cancer-fighting treatments. The company has several drugs in clinical testing, including two bispecific antibodies targeting gastric cancer and solid tumors, as well as an antibody designed to support immune system activity against cancer. NovaBridge works alongside partners such as Bristol Myers Squibb, ABL Bio, and TJ Bio to advance these treatments, and holds a licensing agreement with Ferring International Center SA covering an inflammation-related therapy.
